Research and Markets (http://www.researchandmarkets.com/research/cxvknc/uterine) has announced the addition of the "Uterine Cancer-Pipeline Insights, 2016" report to their offering.
Uterine Cancer-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Uterine Cancer. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.
Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.
The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Uterine Cancer.
The report also assesses the Uterine Cancer therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.
Scope
- The report provides competitive pipeline landscape of Uterine Cancer
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Uterine Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Uterine Cancer and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Key Topics Covered:
- Uterine Cancer Overview
- Uterine Cancer Pipeline Therapeutics
- Uterine Cancer Therapeutics under Development by Companies
- Uterine Cancer Filed and Phase III Products
- Comparative Analysis
- Uterine Cancer Phase II Products
- Comparative Analysis
- Uterine Cancer Phase I and IND Filed Products
- Comparative Analysis
- Uterine Cancer Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Uterine Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Uterine Cancer - Discontinued Products
- Uterine Cancer - Dormant Products
- Companies Involved in Therapeutics Development for Uterine Cancer
For more information visit http://www.researchandmarkets.com/research/cxvknc/uterine
View source version on businesswire.com: http://www.businesswire.com/news/home/20160113005611/en/